Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment
William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating today. Sami Corwin’s rating is ...
Patient death post BEAM-101 doesn’t seem related to Beam drug, says BMO
BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, ...
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
ENDPOINTS NEWS6h
No­vo Nordisk takes For­ma’s sick­le cell treat­ment in­to Phase 3
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...
BioSpace7h
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
FiercePharma8h
Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.
ENDPOINTS NEWS8h
Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death
Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...
Beam falls after fatality in gene editing trial
Beam Therapeutics (NASDAQ:BEAM) fell sharply in the morning hours Tuesday after multiple media reports indicated that a patient has died following the administration of the company's experimental gene ...
Le Lézard9h
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system, today unveiled its ...